Home Healthcare Biotechnology Pediatric Cancer Biomarkers Market

Pediatric Cancer Biomarkers Market Size, Share & Trends Analysis Report By Indication (Lymphoma, Neuroblastoma, Leukemia, CNS Tumors, Others), By Biomarker (Neuron-Specific enolase (NSE), Alpha-Fetoprotien (AFP), ALK (Anaplastic lymphoma receptor tyrosine kinase gene), CD19, CD20, CD22, Others), By End-User (Hospitals, Oncology Centers, Research Institutions, Diagnostic Laboratories) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2026-2034

Last Updated: June 03, 2026 | Author: Mitiksha Koul | Format: | Report Code: SR6516DR | Pages: 110
Overview TOC Segmentation Methodology
Download Free Sample

Market Segmentation

  1. Pediatric Cancer Biomarkers Market, By Indication 2022-2034 (USD MILLION/ Units)
    1. Lymphoma
    2. Neuroblastoma
    3. Leukemia
    4. CNS Tumors
    5. Others
  2. Pediatric Cancer Biomarkers Market, By Biomarker 2022-2034 (USD MILLION/ Units)
    1. Neuron-Specific enolase (NSE)
    2. Alpha-Fetoprotien (AFP)
    3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
    4. CD19, CD20, CD22
    5. Others
  3. Pediatric Cancer Biomarkers Market, By End-User 2022-2034 (USD MILLION/ Units)
    1. Hospitals
    2. Oncology Centers
    3. Research Institutions
    4. Diagnostic Laboratories
  4. Regional Pediatric Cancer Biomarkers Market
    1. North America
      1. North America Pediatric Cancer Biomarkers Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      2. North America Pediatric Cancer Biomarkers Market By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      3. North America Pediatric Cancer Biomarkers Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
      4. U.S.
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      5. Canada
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
    2. Europe
      1. Europe Pediatric Cancer Biomarkers Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      2. Europe Pediatric Cancer Biomarkers Market By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      3. Europe Pediatric Cancer Biomarkers Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
      4. U.K.
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      5. Germany
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      6. France
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      7. Spain
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      8. Italy
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      9. Russia
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      10. Nordic
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      11. Benelux
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      12. Rest of Europe
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
    3. APAC
      1. APAC Pediatric Cancer Biomarkers Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      2. APAC Pediatric Cancer Biomarkers Market By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      3. APAC Pediatric Cancer Biomarkers Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
      4. China
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      5. Korea
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      6. Japan
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      7. India
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      8. Australia
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      9. Taiwan
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      10. South East Asia
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      11. Rest of Asia-Pacific
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
    4. Middle East and Africa
      1. Middle East and Africa Pediatric Cancer Biomarkers Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      2. Middle East and Africa Pediatric Cancer Biomarkers Market By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      3. Middle East and Africa Pediatric Cancer Biomarkers Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
      4. UAE
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      5. Turkey
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      6. Saudi Arabia
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      7. South Africa
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      8. Egypt
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      9. Nigeria
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      10. Rest of MEA
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
    5. LATAM
      1. LATAM Pediatric Cancer Biomarkers Market By Indication 2022-2034 (USD MILLION/ Units)
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
      2. LATAM Pediatric Cancer Biomarkers Market By Biomarker 2022-2034 (USD MILLION/ Units)
        1. Neuron-Specific enolase (NSE)
        2. Alpha-Fetoprotien (AFP)
        3. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        4. CD19, CD20, CD22
        5. Others
      3. LATAM Pediatric Cancer Biomarkers Market By End-User 2022-2034 (USD MILLION/ Units)
        1. Hospitals
        2. Oncology Centers
        3. Research Institutions
        4. Diagnostic Laboratories
      4. Brazil
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      5. Mexico
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      6. Argentina
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      7. Chile
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      8. Colombia
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
      9. Rest of LATAM
        1. Lymphoma
        2. Neuroblastoma
        3. Leukemia
        4. CNS Tumors
        5. Others
        6. Neuron-Specific enolase (NSE)
        7. Alpha-Fetoprotien (AFP)
        8. ALK (Anaplastic lymphoma receptor tyrosine kinase gene)
        9. CD19, CD20, CD22
        10. Others
        11. Hospitals
        12. Oncology Centers
        13. Research Institutions
        14. Diagnostic Laboratories
200+ Trusted Partners
LG Electronics AMCAD Engineering KOBE STEEL LTD. Hindustan National Glass & Industries Limited Voith Group International Paper Hansol Paper Whirlpool Corporation Sony Samsung Electronics Qualcomm Google Fiserv Veto-Pharma Nippon Becton Dickinson Merck Argon Medical Devices Abbott Ajinomoto Denon Doosan Meiji Seika Kaisha Ltd LG Chemicals LCY chemical group Bayer Airrane BASF Toyota Industries Nissan Motors Neenah Mitsubishi Hyundai Motor Company Honda CRP Industries Inc pewag LGE Panasonic Lubrizol Corporation Leonardo Johnson & Johnson HB Fuller MITSUBISHI CHEMICAL Hyundai Mobis Amazon
Download Free Sample
Reach out to us
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)
sales@straitsresearch.com

We are featured on:

Straits Research
Address:
105, Panchshil The Golden Bell,
Koregaon Park Annexe, Mundhwa,
Pune, Maharashtra 411036
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
Duns
DMCA.com Protection Status
lets-encrypt
Secure Payments:
Secure Payments
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.